top
Please input keywords
바이오사이토젠의 비전
바이오사이토젠은 새롭고 창조적인 기술 플랫폼을 바탕으로 신약 개발에 앞장서는 바이오텍입니다. 규모화된 항체 신약 개발 플랫폼 'RenMice HiTS Platform'을 바탕으로, 지속적인 항체의약품 개발을 추진하여, 환자들의 수요를 충족시킬 수 있도록 하겠습니다.
More
연구개발 영역
신약 연구개발의 전 과정을 플랫폼화하여, 저희 바이오사이토젠은 면역항암, 자가면역질환, 대사질환 및 감염병 등의 질병 영역에 대하여 다양한 연구개발중인 파이프라인을 보유하고 있습니다. 여러 질환들에 대하여 높은 효과와 안전성을 갖고 있는 항체의약품을 개발하여 보급하는데 주력하고 있습니다.
More
CD40 mAb-YH003
CTLA-4 mAb - YH001
PD-1 x CD40 BsAbs-YH008
CTLA-4 x OX40 BsAbs-YH006
HER2 x TROP2 BsADCs- YH012
RSV- YH009
바이오사이토젠의 플랫폼
Based on our proprietary RenMice(RenMab, RenLite and RenNano)platform, we have established a system of antibody drug discovery platforms including fully human monoclonal, bispecific antibody,nanobody development,bispecific ADC,GPCR antibody, TCR-like antibody platforms. These platforms can efficiently accelerate large scale innovative antibody drug development process.
More
파트너쉽
BEIJING, March 8, 2023 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC. RenLite is a member of Biocytogen's fully human antibody RenMiceTM family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development. Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.” About RenMiceTM RenMiceTM are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMabTM, RenLite® and RenNanoTM mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs). RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets. As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNanoTM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. Biocytogen’s Contacts Antibody platforms and antibody assets: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
2023.03.08
BEIJING, China, February 27th, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan). Eucure Biopharma retains YH008’s global rights to develop and commercialize YH008 outside Greater China. Under the agreement, Chipscreen NewWay will pay Eucure Biopharma an upfront payment of 40 million RMB, a potential development milestone payment of up to 360 million RMB, a potential sales milestone payment of up to 196 million RMB, as well as tiered royalties on net sales. YH008 is Biocytogen’s independently developed proprietary bispecific antibody for tumor immunotherapy. The IND application for a phase I study of YH008 was cleared by the US FDA and accepted by the Chinese NMPA. “Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialization,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “With this agreement in place, we will work together to accelerate YH008’s entry into the market to benefit patients.” “Biocytogen’s YH008 has unique mechanisms and outstanding precllinical results,” said Dr. Xianping Lu, CEO and President of Chipscreen Biosciences. “This licensing agreement will expand Chipscreen NewWay’s pipeline in the field of antibody drugs and immuno-oncology. I look forward to these fruitful collaborations.” “The unique mechanism of action of YH008 bring together the synergies of immune activation and immunosuppressive blockade, and can reduce toxic side effects and increase safety,” said Dr. Bin Liu, Head of the Center of Antibody Early R&D at Chipscreen NewWay. “The clinical potential of YH008 is worth looking forward to and it is a good addition to the products under development of Chipscreen NewWay. Chipscreen NewWay will rapidly advance the clinical stage research and development of YH008.” About YH008 YH008 is a bispecific antibody that exerts antagonistic and agonistic activities. In vitro and in vivo studies indicate that YH008 can conditionally activate the immune pathway in the tumor microenvironment where certain tumor specific T cells are enriched to avoid systemic non-specific activation. Additionally, YH008 was engineered with an Fc-silent IgG1 isotype to avoid Fc-receptor-mediated non-specific immune activation. YH008 demonstrated superior anti-tumor activity when compared to parental monoclonal antibodies (mAbs) or combination therapy in syngeneic models. In vivo pharmacodynamic studies indicate that YH008 can activate tumor-infiltrating DCs and T cells. In addition, both in vivo studies and GLP toxicology studies indicate improved safety of YH008 compared with benchmark mAbs. About Eucure Biopharma As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit https://www.eucure.com/en/index. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNanoTM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. About Chipscreen In 2001, Chipscreen Biosciences was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created "integrated drug discovery and early evaluation platform based on chemical genetics" as its core competitiveness, Chipscreen Biosciences has now become one of China's leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen, as its headquarters / research and development center / GMP production base, Chengdu, as a regional headquarter / research and development center / GMP production base, Beijing clinical research center and Shanghai commercial center. At present, the company has developed a number of original new drug product lines for tumors, diabetes, and endocrine and autoimmune diseases. In December 2014, the original anti-tumor new drug Chidamide was approved by the China Food and Drug Administration for marketing. Shenzhen Chipscreen Biosciences Co., Ltd. (Stock symbol: 688321.SH) has been listed on the SSE STAR Market on August 12, 2019. About Chipscreen NewWay Biosciences Chipscreen NewWay, affiliated with Chipscreen, is an innovative and R&D-driven biotech company dedicated to developing large molecules and other novel therapeutic modalities, including antibodies/ADC-centered large molecules, and nucleic acid drugs. It develops innovative drugs that meet clinical needs and novel mechanisms of action in multiple therapeutic areas such as oncology and autoimmunity while providing patients with innovative mechanisms and globally leading-based new therapeutic approaches and options. Chipscreen NewWay has built a large molecular R&D center of over 1,800 square meters in Chengdu Hi-Tech Zone and has established an experienced antibody and ADC R&D team from the discovery to the early process development, with a number of in-house and cooperation projects in continuous and rapid advancements. Biocytogen's Contacts Antibody drug assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
2023.02.27
뉴스 & Webinar
More
17
Mar , 2023
Biocytogen to Present 26 Posters and a Booth at AACR 2023
Biocytogen is attending AACR Annual Meeting 2023, held from April 14-19 in Orlando, Florida! For the latest advances in our therapeutic antibody assets and platforms, animal models and service offerings, be sure to stop by at our Booth 723 and visit our 26 posters! Our posters comprise: RenMabTM-Based Fully Human Antibody Discovery Platforms RenNanoTM Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics Poster Number: LB210 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed Discovery of RenNanoTM-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier Poster Number: LB211 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived from HLA Transgenic RenMiceTM Poster Number: 2752 Session: Innovative Assay Technologies Date/Time: April 17, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/2509 The RenMiceTM HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets Poster Number: 5320 Session: High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/5254 Fully Human Monoclonal Antibody Assets 1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity Poster Number: 6436 Session: Immunotherapy Strategies and Mechanisms Date/Time: April 19, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6990 6B5, An Anti-Human B7-H3 Therapeutic Antibody That Enhances Antibody-Dependent Cellular Cytotoxicity and Inhibits Tumor Growth in B7-H3-Humanized Mice Poster Number: 1528 Session: Antibody Drug Conjugates Date/Time: April 17, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/2650 7E1, A Novel Blocking Antibody Targeting Human Anti-Mullerian-Hormone-Receptor II (AMHRII), Elicits Potent Anti-Tumor Activity In vivo Poster Number: 6343 Session: Anticancer Immunotherapeutics Date/Time: April 19, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4058 BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice Poster Number: 6435 Session: Immunotherapy Strategies and Mechanisms Date/Time: April 19, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6976 D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice Poster Number: 1866 Session: Therapeutic Antibodies 1 Date/Time: April 17, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3781 RenLite®-derived Fully Human Bispecific ADC Assets A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy Poster Number: 2977 Session: Therapeutic Antibodies 3 Date/Time: April 17, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3674 YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy Poster Number: 2978 Session: Therapeutic Antibodies 3 Date/Time: April 17, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3670 A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity Poster Number: 6325 Session: Anticancer Immunotherapeutics Date/Time: April 19, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4039 BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET Poster Number: LB212 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer Poster Number: LB216 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy Poster Number: LB215 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1 Poster Number: LB214 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate Poster Number: LB213 Session: Late-Breaking Research: Immunology 2 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: to be disclosed Off-the-Shelf Mouse Models A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies Poster Number: 3233 Session: Combination Immunotherapies 1 Date/Time: April 17, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3126 B-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A Poster Number: 3286 Session: Combination Immunotherapies 2 Date/Time: April 17, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4750 Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution Poster Number: 5208 Session: Novel Preclinical Models for Cancer Immunotherapy Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6987 Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution Poster Number: 5207 Session: Novel Preclinical Models for Cancer Immunotherapy Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6982 Generation of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages Poster Number: 5209 Session: Novel Preclinical Models for Cancer Immunotherapy Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6988 Humanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics Poster Number: 5178 Session: Modifiers of the Tumor Microenvironment Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3613 In vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice Poster Number: 4592 Session: Advances in Angiogenesis Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/5493 In vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage Poster Number: 3993 Session: Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3 Date/Time: April 18, 2023, 9:00 AM – 12:30 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/8652 Novel Humanized CD36 Mouse Model for Therapeutic Studies Poster Number: 5196 Session: Novel Preclinical Models for Cancer Immunotherapy Date/Time: April 18, 2023, 1:30 PM – 5:00 PM Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6977 To schedule a meeting with us, please contact us at BD-Licensing@biocytogen.com. About AACR Annual Meeting The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNanoTM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTMlicensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. Biocytogen’s Contacts Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
15
Mar , 2023
Biocytogen to Host 1-on-1 Meetings at BIO-EUROPE SPRING 2023
Biocytogen’s antibody BD and licensing team is pleased to attend and host 1-on-1 meetings at the 17th annual BIO-Europe Spring, taking place March 20–22, 2023 in Basel, Switzerland. With the successful launch of Biocytogen’s proprietary fully human antibody mice (RenMabTM, RenLite® and RenNanoTM), Biocytogen has developed 6 fully human antibody discovery platforms for development of monoclonal antibodies, bispecific and multi-specific antibodies, nanobodies, bispecific ADCs, TCR-mimic antibodies against intracellular TAAs, and antibodies against GPCRs and other challenging targets. Since the launch of Project Integrum, an initiative to develop therapeutic antibodies for more than 1000+ targets, the company has generated: 5 clinical stage assets: YH003: CD40 mAb in phase II MRCTs; YH001: CTLA-4 mAb in an ongoing phase I clinical trial for the treatment of sarcoma in partnership with TRACON; YH008: PD-1×CD40 bsAb, which received both FDA and NMPA IND clearance; YH002: OX40 mAb in phase I clinical trials in Australia and China; YH004: 4-1BB mAb in phase I clinical trials in Australia and China. Numerous preclinical assets, including: 10 fully human bispecific antibodies (BsAbs): YH006, a fully human CTLA-4×OX40 BsAb generated by the RenLite platform; 20+ bispecific antibody-drug conjugates (BsADCs): YH012, a HER2 x TROP2 BsADC and YH013, an EGFR x cMET BsADC; 40+ TAA-targeting backbones for plug and play. 10+ TCR-mimic (TCRm) antibodies against intracellular tumor-associated antigens (TAAs), including WT-1, KRAS, P53, AFP, GP100、NY-ESO-1, etc; 30+ monoclonal antibodies for novel targets: B7H3, TNFR2, CCR8, Siglec-15, AMHR2 and other novel TAAs, co-stimulatory/co-inhibitory molecules, tumor microenvironment molecules, and GPCRs, among others; 600+ antibody hits: targeting B7H4, DLL3, MUC1, GPRC5D, PSMA, LRRC15 and other therapeutic targets for oncology, inflammatory and autoimmune diseases, infectious diseases, and neurodegenerative disease applications. Biocytogen has reached drug co-development agreements and RenMabTM/RenLite® licensing agreements with companies around the world, including Janssen, Merck KGaA, ADC Therapeutics, Xencor, TRACON, BeiGene, Remegen, and Chipscreen. The company will continue to actively seek partnerships to accelerate the development of novel therapies. To schedule a 1-on-1 meeting with Biocytogen, please contact us at BD-Licensing@biocytogen.com. About BIO-EUROPE SPRING  Over the years, BIO-Europe Spring has become Europe’s largest springtime partnering event. Its international reach makes it a one of a kind offering and gateway to the global life science community. The event will cater to the needs of the entire value chain, start-up and innovator educational programmes, industry trends and outlooks from KOLs, company pitches, professional partnering meetings as well as various networking opportunities are part of the ROI proven feature set. BIO-Europe Spring is produced by EBD Group, the leading partnering firm for the global biotechnology industry, with the support of the Biotechnology Innovation Organization (BIO).     About Biocytogen  Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNanoTM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTMlicensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. Follow Biocytogen on LinkedIn, and on Twitter @Biocytogen_Ab. Biocytogen’s Contacts Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
08
Mar , 2023
Biocytogen Announces RenLite Licensing Agreement with Janssen
BEIJING, March 8, 2023 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC. RenLite is a member of Biocytogen's fully human antibody RenMiceTM family. RenLite mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development. Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.” About RenMiceTM RenMiceTM are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMabTM, RenLite® and RenNanoTM mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs). RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets. As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent. About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNanoTM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn. Biocytogen’s Contacts Antibody platforms and antibody assets: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn
naver-site-verification: naver8a6b0412e3d2d9dd38f1684b831435ac.html